MASH patients with fibrosis are at more risk of severe consequences than you think—even as early as F21

MASH with significant fibrosis (F2/F3) is a progressive liver disease
with an increased risk of major liver-related events1

Spotted animated liver that is in the cirrhosis stage.

Cirrhosis
 

 Dark red liver with dark and light spots that is in the decompensated cirrhosis stage.

Decompensated
cirrhosis

 Spotted yellow liver with abrasions that is in the hepatocellular carcinoma stage.

Hepatocellular
carcinoma

 Spotted yellow liver with abrasions image with scalpel and arrow to denote liver transplant.

Liver transplant
 

 Damaged liver image paired with a skull to denote mortality.

Mortality
 
Spotted animated liver that is in the cirrhosis stage.

Cirrhosis

MASH is a leading cause of liver cirrhosis in the US2

  • Cases of MASH with cirrhosis in adults are expected to increase ~2x from 2020 to 20503

  • 22% of MASH patients with F3 progress to cirrhosis within 2 years4

  • Patients with cirrhosis (F4) have a 42x higher risk of liver-related mortality vs F05

Dark red liver with dark and light spots that is in the decompensated cirrhosis stage.

Decompensated
cirrhosis

33% of MASH patients with compensated cirrhosis progress to decompensated cirrhosis or liver transplant within 4 years6

  • Cases of decompensated cirrhosis in US adults are expected to increase ~3.5x from 2020 to 20503

Spotted yellow liver with abrasions that is in the hepatocellular carcinoma stage.

Hepatocellular
carcinoma

Patients with noncirrhotic MASH have a ~3x increased risk of HCC compared to those with liver disease of other etiologies7

  • HCC can develop in noncirrhotic MASH patients as early as fibrosis stage F28

Spotted yellow liver with abrasions image with scalpel and arrow to denote liver transplant.

Liver transplant

In US adults, MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation9,10

  • The number of liver transplantations due to MASH will increase by ~4x by 20503

Damaged liver image paired with a skull to denote mortality.

Mortality

Fibrosis is the strongest predictor of liver-related mortality5

  • Patients with fibrosis stage F2/F3 have ~10-17x increased risk of liver-related mortality vs those with fibrosis stage F05

Fibrosis progression drives severe liver-related consequences and is fueled by dysfunction of critical liver processes1,11

Fibrosis progression and risks

HCC=hepatocellular carcinoma; MASH=metabolic dysfunction-associated steatohepatitis.

References: 1. Rinella ME et al. Hepatology. 2023;77(5):1797-1835. 2. Tran S et al. Aliment Pharmacol Ther. 2024;60(2):212-223. 3. Le P et al. JAMA Netw Open. 2025;8(1):e2454707. 4. Loomba R, Adams LA. Hepatology. 2019;70(6):1885-1888. 5. Dulai PS et al. Hepatology. 2017;65(5):1557-1565. 6. Allen AM et al. J Hepatol. 2022;77(5):1237-1245. 7. Stine JG et al. Aliment Pharmacol Ther. 2018;48(7):696-703.
8. Kawada N et al. J Gastroenterol. 2009;44(12):1190-1194. 9. Wong RJ, Singal AK. JAMA Netw Open. 2020;3(2):e1920294. 10. Kwong AJ et al. Am J Transplant. 2024;24(2S1):S176-S265. 11. Zeng J et al. United European Gastroenterol J. 2024;12(2):177-186.